Nemaura Medical (NMRD) Peer Comparison
$0.00
$-0.03
(-99.69%)
As on 03-Sep-2026 16:00EDT
Market cap
$0 Mln
Revenue (TTM)
$-2 Mln
P/E Ratio
--
P/B Ratio
122.6
Div. Yield
0 %
Edit
| Nemaura Medical (NMRD) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
-- | 12,650 | 12,007 | 10,638 | 9,762 |
Revenue ($ Mln) |
-2 | 1,505 | 6,164 | 613 | 2,589 |
Net Profit ($ Mln) |
-10.65 | 160.59 | 625.00 | -188.05 | 222.40 |
Net Margin (%) |
685.64 | 10.67 | 5.41 | -30.68 | 8.59 |
RoE (%) |
-- | 10.86 | 11.84 | -28.10 | 3.04 |
Price to Earnings |
-- | 79.29 | 19.52 | -- | 44.47 |
Price-To-Book |
122.56 | 8.31 | 2.34 | 15.27 | 1.36 |
Income Statement ($ Mln)
| Nemaura Medical (NMRD) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.08 | 1,058.52 | 5,549.00 | 314.71 | 2,671.26 |
|
Cost of Revenue
|
1.55 | 375.88 | 1,654.00 | 75.58 | 1,244.32 |
|
Gross Profit
|
-1.48 | 682.64 | 3,895.00 | 239.14 | 1,426.95 |
|
Operating Expenses
|
8.12 | 609.09 | 3,470.00 | 367.84 | 1,089.10 |
|
Operating Profit (EBIT)
|
-9.60 | 73.55 | 425.00 | -128.70 | 337.80 |
|
Other Income
|
-- | -2.33 | -- | 2.38 | 44.78 |
|
Profit before Tax
|
-14.14 | 79.65 | 290.00 | -133.73 | -850.10 |
|
Provision for Tax
|
10.96 | -11.30 | 27.00 | 0.93 | -212.78 |
|
Profit after Tax (Net Income)
|
-14.14 | 90.95 | 263.00 | -134.66 | -637.32 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-14.14 | 90.95 | 263.00 | -99.20 | -3,627.54 |
Liabilities ($ Mln)
| Nemaura Medical (NMRD) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-11.81 | 1,178.94 | 5,217.00 | 461.77 | 8,741.20 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
4.11 | 226.22 | 2,499.00 | 404.63 | 3,035.10 |
|
Current Liabilities
|
22.27 | 151.14 | 2,271.00 | 74.01 | 522.80 |
|
Total Liabilities
|
14.56 | 1,556.31 | 9,987.00 | 940.41 | 12,299.10 |
Assets ($ Mln)
| Nemaura Medical (NMRD) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1.03 | 640.90 | 5,957.00 | 544.95 | 9,250.80 |
|
Current Assets
|
13.54 | 915.40 | 4,030.00 | 395.46 | 3,048.30 |
|
Total Assets
|
14.56 | 1,556.31 | 9,987.00 | 940.41 | 12,299.10 |
|
Total Debt*
|
20.03 | 234.34 | 3,084.00 | 383.74 | 1,405.50 |
|
Net Current Assets
|
-8.73 | 764.26 | 1,759.00 | 321.45 | 2,525.53 |
Cashflow ($ Mln)
| Nemaura Medical (NMRD) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-8.45 | 97.33 | 608.00 | -57.76 | 374.94 |
|
Cash Flow from Investing Activities
|
-0.54 | -16.08 | -448.00 | 14.10 | 20.21 |
|
Cash from Financing Activities
|
2.08 | 16.20 | -200.00 | 15.04 | -425.65 |
|
Net Cash Inflow / Outflow
|
-- | 10.75 | -- | 17.95 | -39.57 |
Ratios
Profitability Ratios
| Nemaura Medical (NMRD) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-101.50 | 6.87 | 3.20 | -15.32 | -6.03 |
|
ROE (%)
|
249.27 | 8.35 | 5.02 | -27.16 | -6.94 |
|
ROA (%)
|
-77.15 | 6.21 | 2.64 | -13.37 | -4.94 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-18,358.00 | 8.59 | 4.74 | -42.79 | -23.86 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Nemaura Medical (NMRD) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.85 | 0.25 | 0.06 | 0.11 | -0.05 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-1.85 | 4,643.16 | 17.94 | -35.75 | 82.43 |
|
EPS Growth (%)
|
0.18 | 45.98 | 0.18 | -0.33 | 0.82 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Nemaura Medical (NMRD) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.83 | 108.66 | 90.54 | -28.85 | -14.50 |
|
Price / Book Value
|
-2.19 | 8.38 | 4.56 | 8.41 | 1.06 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-4.91 | 90.46 | 21.91 | -48.39 | -13.80 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Nemaura Medical (NMRD) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-1.70 | 0.20 | 0.59 | 0.83 | 0.16 |
|
Short term debt to equity ratio
|
-1.43 | 0.01 | 0.15 | 0.00 | 0.00 |
|
Current Ratio
|
0.61 | 6.06 | 1.77 | 5.34 | 5.83 |
|
Quick Ratio
|
0.53 | 3.49 | 0.72 | 4.78 | 4.34 |
|
Interest Coverage
|
-1.21 | 46.80 | 5.59 | -8.81 | -16.20 |
Operating Efficiency Ratios
| Nemaura Medical (NMRD) | Penumbra (PEN) | Smith & Nephew SNATS - ADR | Glaukos Corp (GKOS) | Bio-Rad Laboratories | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
531.71 | 19.06 | 19.08 | 12.66 | 18.31 |
|
Asset Turnover
|
0.00 | 0.72 | 0.56 | 0.31 | 0.21 |
|
Receivable days
|
1,211.14 | 69.90 | 68.65 | 44.06 | 67.25 |
|
Inventory Days
|
381.21 | 350.81 | 507.91 | 192.90 | 220.12 |
|
Payable days
|
54.43 | 26.16 | 225.80 | 67.28 | 41.04 |
|
Cash Conversion Cycle
|
1,537.93 | 394.55 | 350.76 | 169.68 | 246.33 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
